Ophthotech Corp (OPHT) 51.11 $OPHT
Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:19AM CST
Alnylam's (ALNY) fourth-quarter 2014 loss of 28 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 51 cents per share.
MON: 124.77 (+2.00), ALNY: 95.54 (+1.67), MDCO: 29.79 (+0.91), OPHT: 51.11 (+0.12)
Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:06AM CST
Genomic Health (GHDX) delivered mixed financial numbers in fourth-quarter 2014 with bottom-line beat but revenue miss.
BMRN: 100.76 (+1.98), OPHT: 51.11 (+0.12), GHDX: 31.12 (+0.28), AFFX: 11.45 (+0.02)
Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:20PM CST
Alkermes (ALKS) reported positive top-line data from an early-stage study on its experimental multiple sclerosis treatment, ALKS 8700.
BIIB: 391.66 (-0.45), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13), ALKS: 71.40 (-1.89)
AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:30AM CST
AMAG Pharmaceuticals (AMAG) reported a fourth-quarter 2014 loss of 2 cents per share, narrower than the year-ago loss of 17 cents per share.
OPHT: 51.11 (+0.12), AMAG: 41.49 (+0.23), PRTA: 22.89 (+0.13)
Theravance/Glaxo's Asthma Drug Under FDA Panel Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:36PM CST
Theravance (THRX) and partner GlaxoSmithKline's (GSK) asthma drug, Breo Ellipta is scheduled to be reviewed by the FDA's advisory panel on Mar 19, 2015.
OPHT: 51.11 (+0.12), TBPH: 18.51 (+0.28), GSK: 47.94 (+1.99), THRX: 14.85 (+1.00)
Does This Small Biotech Have the Making of a Blockbuster?
Motley Fool Staff - Motley Fool - Sat Feb 07, 8:59AM CST
Source: Flickr user Stockmonkeys.com. When it comes to developing billion-dollar blockbuster drugs, the odds are stacked against biotech companies. About 90% of drugs that enter clinical trials fail, and of those that do eventually get approved,...
OPHT: 51.11 (+0.12), ICPT: 209.12 (+7.12), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Pfizer Set to Acquire Hospira for $17B, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 2:44PM CST
Pfizer (PFE) is set to acquire Hospira (HSP) in an all-cash transaction valued at about $17 billion or $90 per share which will strengthen its Global Established Pharmaceutical business.
IPXL: 39.51 (+0.69), PFE: 34.64 (-0.23), OPHT: 51.11 (+0.12), HSP: 87.35 (unch)
Ophthotech Corporation to Present at the Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 11:35 a.m. EST.
OPHT: 51.11 (+0.12)
Protalix Finishes Patient Enrollment for Fabry Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 3:39PM CST
Protalix (PLX) completed patient enrolment in a phase I/II study on its Fabry disease candidate PRX-102.
SHPG: 239.82 (+6.11), OPHT: 51.11 (+0.12), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82)
Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:58AM CST
Although Myriad's (MYGN) second-quarter fiscal 2015 results beat the Zacks Consensus Estimate on both the top and bottom line fronts, on a year-over-year basis, both the figures declined substantially.
ACAD: 34.21 (+0.37), MYGN: 34.03 (+0.40), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13)
Isis Pharmaceuticals (ISIS) Crumbles: Stock Falls by 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:46AM CST
Isis Pharmaceutical saw a big move last session, as the company’s shares fell by over nearly 6% which continued the downtrend for the company
ISIS: 63.86 (-0.43), OPHT: 51.11 (+0.12)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), OPHT: 51.11 (+0.12), LMNX: 15.45 (+0.02), ENTA: 33.30 (-0.44), ORPN: 7.17 (+0.04), EVOK: 5.41 (-0.10), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SSYS: 67.16 (-0.34), AKBA: 9.32 (+0.51), VBLT: 14.11 (+0.24)
Heska Corporation (HSKA) Jumps: Stock Moves 7.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:32AM CST
Heska Corporation (HSKA) was a big mover last session, as the company saw its shares rise more than 7% on the day.
HSKA: 20.95 (+0.07), OPHT: 51.11 (+0.12)
This Tiny Biotech Hopes to Capture a Share of This $6 Billion Market
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 02, 7:02AM CST
Source: Flickr user Ali T . Ophthotech Corporation is developing a new drug that may improve results for Novartis and Regeneron 's top-selling vision loss therapies. If Ophthotech's late-stage trials pan out, Ophthotech could have a...
JPM: 59.67 (+0.10), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
3 Small-Cap Biotech Stocks That Could Be Top Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 31, 12:06PM CST
Source: Flickr user stockmonkeys.com . The pop-and-drop nature of the biotech industry makes owning stocks in the sector particularly dicey. But for investors willing to take on the risk of failure, a number of intriguing small-cap biotech...
JNJ: 99.62 (+1.18), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), PFE: 34.64 (-0.23), OPHT: 51.11 (+0.12), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Vertex Pharmaceuticals Slumps: VRTX Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 7:52AM CST
Vertex Pharmaceuticals saw a big move last session, as the company’s shares fell nearly 6% on the day.
VRTX: 113.66 (+4.03), OPHT: 51.11 (+0.12)
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:07PM CST
BioDelivery (BDSI) entered into an agreement with Meda to obtain marketing authorizations for Onsolis.
BDSI: 14.92 (+0.93), OPHT: 51.11 (+0.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Illumina Tops Q4 Earnings on Solid Revenues, Margin Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:30AM CST
Illumina's (ILMN) full year 2014 adjusted earnings came in at $2.74 per share, beating the Zacks Consensus Estimate by 3.4% and reflecting an improvement of 52.2% from the year-ago quarter's equivalent figure.
OPHT: 51.11 (+0.12), ILMN: 198.54 (+1.81), PRTA: 22.89 (+0.13), RGDO: 1.17 (+0.02)
5 Tiny Biotech Stocks to Own in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 17, 5:51AM CST
Biotech stocks are among the market's riskiest, but investors willing to accept the potential for pipeline failure might consider owning these five small-cap biotech stocks in 2015. All five have intriguing therapies in late-stage clinical trials,...
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), XLRN: 38.02 (+0.07)
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jan 13, 12:00AM CST
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
INCY: 75.94 (+0.28), OPHT: 51.11 (+0.12), AGIO: 118.55 (+0.11), OSUR: 8.13 (+0.06), XNPT: 6.69 (-0.21)
Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:19AM CST
Alnylam's (ALNY) fourth-quarter 2014 loss of 28 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 51 cents per share.
MON: 124.77 (+2.00), ALNY: 95.54 (+1.67), MDCO: 29.79 (+0.91), OPHT: 51.11 (+0.12)
Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:06AM CST
Genomic Health (GHDX) delivered mixed financial numbers in fourth-quarter 2014 with bottom-line beat but revenue miss.
BMRN: 100.76 (+1.98), OPHT: 51.11 (+0.12), GHDX: 31.12 (+0.28), AFFX: 11.45 (+0.02)
Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:20PM CST
Alkermes (ALKS) reported positive top-line data from an early-stage study on its experimental multiple sclerosis treatment, ALKS 8700.
BIIB: 391.66 (-0.45), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13), ALKS: 71.40 (-1.89)
AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:30AM CST
AMAG Pharmaceuticals (AMAG) reported a fourth-quarter 2014 loss of 2 cents per share, narrower than the year-ago loss of 17 cents per share.
OPHT: 51.11 (+0.12), AMAG: 41.49 (+0.23), PRTA: 22.89 (+0.13)
Theravance/Glaxo's Asthma Drug Under FDA Panel Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:36PM CST
Theravance (THRX) and partner GlaxoSmithKline's (GSK) asthma drug, Breo Ellipta is scheduled to be reviewed by the FDA's advisory panel on Mar 19, 2015.
OPHT: 51.11 (+0.12), TBPH: 18.51 (+0.28), GSK: 47.94 (+1.99), THRX: 14.85 (+1.00)
Does This Small Biotech Have the Making of a Blockbuster?
Motley Fool Staff - Motley Fool - Sat Feb 07, 8:59AM CST
Source: Flickr user Stockmonkeys.com. When it comes to developing billion-dollar blockbuster drugs, the odds are stacked against biotech companies. About 90% of drugs that enter clinical trials fail, and of those that do eventually get approved,...
OPHT: 51.11 (+0.12), ICPT: 209.12 (+7.12), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Pfizer Set to Acquire Hospira for $17B, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 2:44PM CST
Pfizer (PFE) is set to acquire Hospira (HSP) in an all-cash transaction valued at about $17 billion or $90 per share which will strengthen its Global Established Pharmaceutical business.
IPXL: 39.51 (+0.69), PFE: 34.64 (-0.23), OPHT: 51.11 (+0.12), HSP: 87.35 (unch)
Ophthotech Corporation to Present at the Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 11:35 a.m. EST.
OPHT: 51.11 (+0.12)
Protalix Finishes Patient Enrollment for Fabry Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 3:39PM CST
Protalix (PLX) completed patient enrolment in a phase I/II study on its Fabry disease candidate PRX-102.
SHPG: 239.82 (+6.11), OPHT: 51.11 (+0.12), PLX: 1.84 (-0.04), SNY: 49.42 (+0.82)
Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:58AM CST
Although Myriad's (MYGN) second-quarter fiscal 2015 results beat the Zacks Consensus Estimate on both the top and bottom line fronts, on a year-over-year basis, both the figures declined substantially.
ACAD: 34.21 (+0.37), MYGN: 34.03 (+0.40), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13)
Isis Pharmaceuticals (ISIS) Crumbles: Stock Falls by 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:46AM CST
Isis Pharmaceutical saw a big move last session, as the company’s shares fell by over nearly 6% which continued the downtrend for the company
ISIS: 63.86 (-0.43), OPHT: 51.11 (+0.12)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), OPHT: 51.11 (+0.12), LMNX: 15.45 (+0.02), ENTA: 33.30 (-0.44), ORPN: 7.17 (+0.04), EVOK: 5.41 (-0.10), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SSYS: 67.16 (-0.34), AKBA: 9.32 (+0.51), VBLT: 14.11 (+0.24)
Heska Corporation (HSKA) Jumps: Stock Moves 7.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:32AM CST
Heska Corporation (HSKA) was a big mover last session, as the company saw its shares rise more than 7% on the day.
HSKA: 20.95 (+0.07), OPHT: 51.11 (+0.12)
This Tiny Biotech Hopes to Capture a Share of This $6 Billion Market
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 02, 7:02AM CST
Source: Flickr user Ali T . Ophthotech Corporation is developing a new drug that may improve results for Novartis and Regeneron 's top-selling vision loss therapies. If Ophthotech's late-stage trials pan out, Ophthotech could have a...
JPM: 59.67 (+0.10), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
3 Small-Cap Biotech Stocks That Could Be Top Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 31, 12:06PM CST
Source: Flickr user stockmonkeys.com . The pop-and-drop nature of the biotech industry makes owning stocks in the sector particularly dicey. But for investors willing to take on the risk of failure, a number of intriguing small-cap biotech...
JNJ: 99.62 (+1.18), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), PFE: 34.64 (-0.23), OPHT: 51.11 (+0.12), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Vertex Pharmaceuticals Slumps: VRTX Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 7:52AM CST
Vertex Pharmaceuticals saw a big move last session, as the company’s shares fell nearly 6% on the day.
VRTX: 113.66 (+4.03), OPHT: 51.11 (+0.12)
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:07PM CST
BioDelivery (BDSI) entered into an agreement with Meda to obtain marketing authorizations for Onsolis.
BDSI: 14.92 (+0.93), OPHT: 51.11 (+0.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Illumina Tops Q4 Earnings on Solid Revenues, Margin Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:30AM CST
Illumina's (ILMN) full year 2014 adjusted earnings came in at $2.74 per share, beating the Zacks Consensus Estimate by 3.4% and reflecting an improvement of 52.2% from the year-ago quarter's equivalent figure.
OPHT: 51.11 (+0.12), ILMN: 198.54 (+1.81), PRTA: 22.89 (+0.13), RGDO: 1.17 (+0.02)
5 Tiny Biotech Stocks to Own in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 17, 5:51AM CST
Biotech stocks are among the market's riskiest, but investors willing to accept the potential for pipeline failure might consider owning these five small-cap biotech stocks in 2015. All five have intriguing therapies in late-stage clinical trials,...
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), XLRN: 38.02 (+0.07)
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jan 13, 12:00AM CST
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
INCY: 75.94 (+0.28), OPHT: 51.11 (+0.12), AGIO: 118.55 (+0.11), OSUR: 8.13 (+0.06), XNPT: 6.69 (-0.21)
